Alexion Pharmaceuticals, Inc. - Strategy, SWOT and Corporate Finance Report
Alexion Pharmaceuticals, Inc. - Strategy, SWOT and Corporate Finance Report
Abstract
Summary
Alexion Pharmaceuticals, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company.
Key Highlights
Alexion Pharmaceuticals, Inc. (Alexion or 'the company') is a biopharmaceutical company involved in the innovation, development, and commercialization of life-transforming therapeutic products. The company focuses on the therapeutic areas such as Neurology, Hematology, Nephrology and Metabolic disorders. Its product portfolio comprises Soliris (eculizumab) for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), and anti-acetylcholine receptor (AchR) antibody-positive generalized myasthenia gravis (gMG); Strensiq (asfotase alfa) for the treatment of patients with hypophosphatasia; and Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency. The company primarily operates in the US, Europe and Asia-Pacific. The company is headquartered in New Haven, Connecticut, the US.
Scope
- Detailed information on Alexion Pharmaceuticals, Inc. required for business and competitor intelligence needs
- A study of the major internal and external factors affecting Alexion Pharmaceuticals, Inc. in the form of a SWOT analysis
- An in-depth view of the business model of Alexion Pharmaceuticals, Inc. including a breakdown and examination of key business segments
- Intelligence on Alexion Pharmaceuticals, Inc.'s mergers and acquisitions (MandA), strategic partnerships and alliances, capital raising, private equity transactions, and financial and legal advisors
- News about Alexion Pharmaceuticals, Inc., such as business expansion, restructuring, and contract wins
- Large number of easy-to-grasp charts and graphs that present important data and key trends
Reasons to Buy
- Gain understanding of Alexion Pharmaceuticals, Inc. and the factors that influence its strategies.
- Track strategic initiatives of the company and latest corporate news and actions.
- Assess Alexion Pharmaceuticals, Inc. as a prospective partner, vendor or supplier.
- Support sales activities by understanding your customers' businesses better.
- Stay up to date on Alexion Pharmaceuticals, Inc.'s business structure, strategy and prospects.
Content
Table of Contents
Company Snapshot
Alexion Pharmaceuticals, Inc.: Company Overview
Alexion Pharmaceuticals, Inc.: Overview and Key Facts
Alexion Pharmaceuticals, Inc.: Overview
Alexion Pharmaceuticals, Inc.: Key Facts
Alexion Pharmaceuticals, Inc.: Key Employees
Alexion Pharmaceuticals, Inc.: Key Employee Biographies
Alexion Pharmaceuticals, Inc.: Major Products and Services
Alexion Pharmaceuticals, Inc.: Company History
Alexion Pharmaceuticals, Inc.: Management Statement
Alexion Pharmaceuticals, Inc.: Locations and Subsidiaries
Alexion Pharmaceuticals, Inc.: Key Competitors
Alexion Pharmaceuticals, Inc.: Company Analysis
Alexion Pharmaceuticals, Inc.: Business Description
Alexion Pharmaceuticals, Inc.: SWOT Analysis
Alexion Pharmaceuticals, Inc.: SWOT Overview
Alexion Pharmaceuticals, Inc.: Strengths
Alexion Pharmaceuticals, Inc.: Weaknesses
Alexion Pharmaceuticals, Inc.: Opportunities
Alexion Pharmaceuticals, Inc.: Threats
Alexion Pharmaceuticals, Inc.: Corporate Financial Deals Activity
Alexion Pharmaceuticals, Inc.: Financial Deals Overview
Alexion Pharmaceuticals, Inc.: Targets and Partners
Alexion Pharmaceuticals, Inc.: Top Deals 2018 - 2022YTD*
Alexion Pharmaceuticals, Inc.: Advisors
Alexion Pharmaceuticals, Inc.: Top Legal Advisors
Alexion Pharmaceuticals, Inc.: Top Financial Advisors
Alexion Pharmaceuticals, Inc.: Mergers and Acquisitions
Alexion Pharmaceuticals, Inc.: Partnership
Alexion Pharmaceuticals, Inc.: Divestments
Alexion Pharmaceuticals, Inc.: Private Equity and Ownership
Alexion Pharmaceuticals, Inc.: Recent Developments
Alexion Pharmaceuticals, Inc.: News and Events Summary
Alexion Pharmaceuticals, Inc.: Contracts
Alexion Pharmaceuticals, Inc.: Regulatory and Legal Events
Alexion Pharmaceuticals, Inc.: Research & Development
Appendix
Contact Us
Methodology
About MarketLine
List Of Tables
Table 1: Alexion Pharmaceuticals, Inc.: Key Facts
Table 2: Alexion Pharmaceuticals, Inc.: Key Employees
Table 3: Alexion Pharmaceuticals, Inc.: Company History
Table 4: Alexion Pharmaceuticals, Inc.: Locations and Subsidiaries
Table 5: Alexion Pharmaceuticals, Inc.: Key Competitors
Table 6: Alexion Pharmaceuticals, Inc.: Deal Activity by Deal Type - Volume (TTM*)
Table 7: Alexion Pharmaceuticals, Inc.: M&A Activity by Geography (TTM*)
Table 8: Alexion Pharmaceuticals, Inc.: Deal Activity by Deal Type - Volume (2018 - YTD*2022)
Table 9: Alexion Pharmaceuticals, Inc.: M&A Average Deal Size - Value (US$m)
Table 10: Alexion Pharmaceuticals, Inc.: Targets and Partners
Table 11: Alexion Pharmaceuticals, Inc.: Top Deals 2018 - 2022YTD*
Table 12: Alexion Pharmaceuticals, Inc.: Legal Advisor Ranking by Value (US$m)
Table 13: Alexion Pharmaceuticals, Inc.: Financial Advisor Ranking by Value (US$m)
Table 14: Alexion Pharmaceuticals, Inc.: M&A Volume and Value Trend (2018 - YTD*2022)
Table 15: Alexion Pharmaceuticals, Inc.: M&A Activity by Geography (2018 - YTD*2022)
Table 16: Alexion Pharmaceuticals, Inc.: Partnership Volume and Value Trend (2018 - YTD*2022)
Table 17: Alexion Pharmaceuticals, Inc.: Partnership Trend by Deal Type (2018 - YTD*2022)
Table 18: Alexion Pharmaceuticals, Inc.: Divestments Volume and Value Trend (2018 - YTD*2022)
Table 19: Alexion Pharmaceuticals, Inc.: Private Equity and Ownership Volume and Value Trend (2018 - YTD*2022)
Table 20: Alexion Pharmaceuticals, Inc.: Private Equity and Ownership Volume by Deal Type (2018 - YTD*2022)
Table 21: Alexion Pharmaceuticals, Inc.: News and Events Summary
Table 22: Alexion Pharmaceuticals, Inc.: Contracts
Table 23: Alexion Pharmaceuticals, Inc.: Regulatory and Legal Events
Table 24: Alexion Pharmaceuticals, Inc.: Research & Development
List Of Figures
Figure 1: Alexion Pharmaceuticals, Inc.: Deal Activity by Deal Type - Volume (TTM*)
Figure 2: Alexion Pharmaceuticals, Inc.: M&A Activity by Geography (TTM*)
Figure 3: Alexion Pharmaceuticals, Inc.: Deal Activity by Deal Type - Volume (2018 - YTD*2022)
Figure 4: Alexion Pharmaceuticals, Inc.: M&A Average Deal Size - Value (US$m)
Figure 5: Alexion Pharmaceuticals, Inc.: M&A Volume and Value Trend (2018 - YTD*2022)
Figure 6: Alexion Pharmaceuticals, Inc.: M&A Activity by Geography (2018 - YTD*2022)
Figure 7: Alexion Pharmaceuticals, Inc.: Partnership Volume and Value Trend (2018 - YTD*2022)
Figure 8: Alexion Pharmaceuticals, Inc.: Partnership Trend by Deal Type (2018 - YTD*2022)
Figure 9: Alexion Pharmaceuticals, Inc.: Divestments Volume and Value Trend (2018 - YTD*2022)
Figure 10: Alexion Pharmaceuticals, Inc.: Private Equity and Ownership Volume and Value Trend (2018 - YTD*2022)
Figure 11: Alexion Pharmaceuticals, Inc.: Private Equity and Ownership Volume by Deal Type (2018 - YTD*2022)
Summary
Alexion Pharmaceuticals, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company.
Key Highlights
Alexion Pharmaceuticals, Inc. (Alexion or 'the company') is a biopharmaceutical company involved in the innovation, development, and commercialization of life-transforming therapeutic products. The company focuses on the therapeutic areas such as Neurology, Hematology, Nephrology and Metabolic disorders. Its product portfolio comprises Soliris (eculizumab) for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), and anti-acetylcholine receptor (AchR) antibody-positive generalized myasthenia gravis (gMG); Strensiq (asfotase alfa) for the treatment of patients with hypophosphatasia; and Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency. The company primarily operates in the US, Europe and Asia-Pacific. The company is headquartered in New Haven, Connecticut, the US.
Scope
- Detailed information on Alexion Pharmaceuticals, Inc. required for business and competitor intelligence needs
- A study of the major internal and external factors affecting Alexion Pharmaceuticals, Inc. in the form of a SWOT analysis
- An in-depth view of the business model of Alexion Pharmaceuticals, Inc. including a breakdown and examination of key business segments
- Intelligence on Alexion Pharmaceuticals, Inc.'s mergers and acquisitions (MandA), strategic partnerships and alliances, capital raising, private equity transactions, and financial and legal advisors
- News about Alexion Pharmaceuticals, Inc., such as business expansion, restructuring, and contract wins
- Large number of easy-to-grasp charts and graphs that present important data and key trends
Reasons to Buy
- Gain understanding of Alexion Pharmaceuticals, Inc. and the factors that influence its strategies.
- Track strategic initiatives of the company and latest corporate news and actions.
- Assess Alexion Pharmaceuticals, Inc. as a prospective partner, vendor or supplier.
- Support sales activities by understanding your customers' businesses better.
- Stay up to date on Alexion Pharmaceuticals, Inc.'s business structure, strategy and prospects.
Table of Contents
Company Snapshot
Alexion Pharmaceuticals, Inc.: Company Overview
Alexion Pharmaceuticals, Inc.: Overview and Key Facts
Alexion Pharmaceuticals, Inc.: Overview
Alexion Pharmaceuticals, Inc.: Key Facts
Alexion Pharmaceuticals, Inc.: Key Employees
Alexion Pharmaceuticals, Inc.: Key Employee Biographies
Alexion Pharmaceuticals, Inc.: Major Products and Services
Alexion Pharmaceuticals, Inc.: Company History
Alexion Pharmaceuticals, Inc.: Management Statement
Alexion Pharmaceuticals, Inc.: Locations and Subsidiaries
Alexion Pharmaceuticals, Inc.: Key Competitors
Alexion Pharmaceuticals, Inc.: Company Analysis
Alexion Pharmaceuticals, Inc.: Business Description
Alexion Pharmaceuticals, Inc.: SWOT Analysis
Alexion Pharmaceuticals, Inc.: SWOT Overview
Alexion Pharmaceuticals, Inc.: Strengths
Alexion Pharmaceuticals, Inc.: Weaknesses
Alexion Pharmaceuticals, Inc.: Opportunities
Alexion Pharmaceuticals, Inc.: Threats
Alexion Pharmaceuticals, Inc.: Corporate Financial Deals Activity
Alexion Pharmaceuticals, Inc.: Financial Deals Overview
Alexion Pharmaceuticals, Inc.: Targets and Partners
Alexion Pharmaceuticals, Inc.: Top Deals 2018 - 2022YTD*
Alexion Pharmaceuticals, Inc.: Advisors
Alexion Pharmaceuticals, Inc.: Top Legal Advisors
Alexion Pharmaceuticals, Inc.: Top Financial Advisors
Alexion Pharmaceuticals, Inc.: Mergers and Acquisitions
Alexion Pharmaceuticals, Inc.: Partnership
Alexion Pharmaceuticals, Inc.: Divestments
Alexion Pharmaceuticals, Inc.: Private Equity and Ownership
Alexion Pharmaceuticals, Inc.: Recent Developments
Alexion Pharmaceuticals, Inc.: News and Events Summary
Alexion Pharmaceuticals, Inc.: Contracts
Alexion Pharmaceuticals, Inc.: Regulatory and Legal Events
Alexion Pharmaceuticals, Inc.: Research & Development
Appendix
Contact Us
Methodology
About MarketLine
List Of Tables
Table 1: Alexion Pharmaceuticals, Inc.: Key Facts
Table 2: Alexion Pharmaceuticals, Inc.: Key Employees
Table 3: Alexion Pharmaceuticals, Inc.: Company History
Table 4: Alexion Pharmaceuticals, Inc.: Locations and Subsidiaries
Table 5: Alexion Pharmaceuticals, Inc.: Key Competitors
Table 6: Alexion Pharmaceuticals, Inc.: Deal Activity by Deal Type - Volume (TTM*)
Table 7: Alexion Pharmaceuticals, Inc.: M&A Activity by Geography (TTM*)
Table 8: Alexion Pharmaceuticals, Inc.: Deal Activity by Deal Type - Volume (2018 - YTD*2022)
Table 9: Alexion Pharmaceuticals, Inc.: M&A Average Deal Size - Value (US$m)
Table 10: Alexion Pharmaceuticals, Inc.: Targets and Partners
Table 11: Alexion Pharmaceuticals, Inc.: Top Deals 2018 - 2022YTD*
Table 12: Alexion Pharmaceuticals, Inc.: Legal Advisor Ranking by Value (US$m)
Table 13: Alexion Pharmaceuticals, Inc.: Financial Advisor Ranking by Value (US$m)
Table 14: Alexion Pharmaceuticals, Inc.: M&A Volume and Value Trend (2018 - YTD*2022)
Table 15: Alexion Pharmaceuticals, Inc.: M&A Activity by Geography (2018 - YTD*2022)
Table 16: Alexion Pharmaceuticals, Inc.: Partnership Volume and Value Trend (2018 - YTD*2022)
Table 17: Alexion Pharmaceuticals, Inc.: Partnership Trend by Deal Type (2018 - YTD*2022)
Table 18: Alexion Pharmaceuticals, Inc.: Divestments Volume and Value Trend (2018 - YTD*2022)
Table 19: Alexion Pharmaceuticals, Inc.: Private Equity and Ownership Volume and Value Trend (2018 - YTD*2022)
Table 20: Alexion Pharmaceuticals, Inc.: Private Equity and Ownership Volume by Deal Type (2018 - YTD*2022)
Table 21: Alexion Pharmaceuticals, Inc.: News and Events Summary
Table 22: Alexion Pharmaceuticals, Inc.: Contracts
Table 23: Alexion Pharmaceuticals, Inc.: Regulatory and Legal Events
Table 24: Alexion Pharmaceuticals, Inc.: Research & Development
List Of Figures
Figure 1: Alexion Pharmaceuticals, Inc.: Deal Activity by Deal Type - Volume (TTM*)
Figure 2: Alexion Pharmaceuticals, Inc.: M&A Activity by Geography (TTM*)
Figure 3: Alexion Pharmaceuticals, Inc.: Deal Activity by Deal Type - Volume (2018 - YTD*2022)
Figure 4: Alexion Pharmaceuticals, Inc.: M&A Average Deal Size - Value (US$m)
Figure 5: Alexion Pharmaceuticals, Inc.: M&A Volume and Value Trend (2018 - YTD*2022)
Figure 6: Alexion Pharmaceuticals, Inc.: M&A Activity by Geography (2018 - YTD*2022)
Figure 7: Alexion Pharmaceuticals, Inc.: Partnership Volume and Value Trend (2018 - YTD*2022)
Figure 8: Alexion Pharmaceuticals, Inc.: Partnership Trend by Deal Type (2018 - YTD*2022)
Figure 9: Alexion Pharmaceuticals, Inc.: Divestments Volume and Value Trend (2018 - YTD*2022)
Figure 10: Alexion Pharmaceuticals, Inc.: Private Equity and Ownership Volume and Value Trend (2018 - YTD*2022)
Figure 11: Alexion Pharmaceuticals, Inc.: Private Equity and Ownership Volume by Deal Type (2018 - YTD*2022)
Related Report
